Select features to define your cohort

Patient ID Age at Diagnosis Sex Ethnicity Menopausal Status Family History Family History Relative BRCA Status Definition ER PR HER2 Tumour Grade Tumour Size Lymph Node Survival Status Followup (Years) Recurrence Metastasis Genetic Ancestry Location hidden
1007 77 female Not specified postmenopausal yes yes unknown primary Negative Negative Negative Grade 3 20 Negative Alive 11.3 NA NA European Barts LP3001415-DNA_H09
1203 43 female White - British premenopausal yes no unknown primary Negative Negative Negative Grade 3 27 Negative Alive 8.7 NA NA European Barts LP3001381-DNA_F01
1263 80 female White - British postmenopausal yes no unknown primary Negative Negative Negative Grade 3 38 Negative Dead 7.3 NA NA European Barts LP3001415-DNA_F09
1506 46 female White - British postmenopausal yes yes BRCA1 primary Negative Negative Negative Grade 3 35 Negative Alive 9.2 NA NA European Barts LP3001381-DNA_C01
1509 62 female Black or Black British - Caribbean postmenopausal yes yes unknown primary Borderline Negative Negative Grade 3 45 Positive Alive 7.8 NA CL African Barts LP3001415-DNA_D08
1633 46 female White - Any other background premenopausal yes no BRCA1 primary Negative Negative Negative Grade 3 22 Negative Alive 7.8 NA NA European Barts LP3001415-DNA_G10
1666 66 female White - British postmenopausal yes yes unknown primary Negative Negative Negative Grade 3 13 Negative Alive 8.5 NA NA European Barts LP3001415-DNA_C09
1759 62 female White - Any other background postmenopausal no no unknown primary Negative Negative Negative Grade 3 18 Positive Alive 6.6 NA NA European Barts LP3001415-DNA_C08
1903 76 female White - British postmenopausal unknown unknown unknown primary Negative Negative Negative Grade 3 28 Negative Alive 8.2 NA NA European Barts LP3001381-DNA_A01
1908 42 female White - Any other background premenopausal yes no BRCA1 primary Negative Negative Negative Grade 3 23 Positive Alive 8.3 NA NA European Barts LP3001415-DNA_H08
1941 74 female White - British postmenopausal yes no unknown primary Negative Negative Negative Grade 3 15 Negative Dead 6.8 NA NA European Barts LP3001415-DNA_B10
1979 55 female Black or Black British - Caribbean not recorded yes yes BRCA1 primary Negative Negative Negative Grade 3 6 Negative Alive 7.8 NA NA African Barts LP3001415-DNA_C10
1987 70 female White - Irish postmenopausal no no unknown primary Negative Negative Negative Grade 3 22 + 20 + 4 Positive Dead 5.5 yes yes European Barts LP3001415-DNA_C04
2061 58 female White - British postmenopausal unknown unknown unknown primary Borderline Negative Negative Grade 3 24 Negative Alive 7.8 NA CL European Barts LP3001415-DNA_B08
2163 39 female White - Any other background premenopausal no no unknown primary Negative Negative Negative Grade 3 60 Positive Alive 7.3 NA NA European Barts LP3001381-DNA_A02
2527 82 female Black or Black British - Any other Black background postmenopausal unknown no unknown primary Negative Negative Negative Grade 3 20 Negative Dead 4.3 yes yes African Barts LP3001381-DNA_B02
2536 66 female Black or Black British - Caribbean postmenopausal yes no unknown primary Negative Negative Negative Grade 2 16 + 7 Negative Alive 4.5 NA NA African Barts LP3001415-DNA_A07
2609 59 female White postmenopausal yes no unknown primary Negative Negative Negative Grade 3 58 Negative Alive 5.9 NA NA Admix Barts LP3001415-DNA_D07
2680 50 female White - Any other background perimenopausal no no unknown primary Negative Negative Negative Grade 3 19 Negative Alive 3.9 NA NA American Barts LP3001415-DNA_B09
2753 74 female Black or Black British - Caribbean postmenopausal unknown unknown unknown primary Negative Negative Negative Grade 3 42 Positive Alive 5.3 NA NA African Barts LP3001415-DNA_A08
2819 44 female Asian or Asian British - Indian premenopausal no no BRCA1 primary Negative Negative Negative Grade 3 22 Negative Alive 4.3 NA NA South Asian Barts LP3001381-DNA_E01
2842 51 female Asian or Asian British - Bangladeshi premenopausal yes yes unknown primary Negative Negative Negative Grade 3 13 Negative Alive 9.8 NA CL South Asian Barts LP3001415-DNA_A09
2953 66 female White - British postmenopausal no no unknown primary Negative Negative Negative Grade 3 17 Negative Alive 4.7 NA NA European Barts LP3001415-DNA_A10
D10271 75 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 3 20 Negative Alive 3.3 NA NA European Dundee LP3001415-DNA_G02
D10466 75 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 3 39 Negative Dead 2.6 NA NA European Dundee LP3001415-DNA_G03
D10540 64 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 17 Negative Dead 2.7 NA NA European Dundee LP3001415-DNA_G04
D10921 49 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 18 Negative Alive 0.4 NA NA European Dundee LP3001415-DNA_C06
D11098 57 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 10 Negative Alive 2.2 NA NA European Dundee LP3001415-DNA_A01
D11120 70 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 40 Positive Dead 0.5 NA NA European Dundee LP3001415-DNA_H02
D11278 71 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 3 17 Negative Alive 1.0 NA NA European Dundee LP3001415-DNA_H03
D11327 62 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 3 32 Negative Alive 0.5 NA NA European Dundee LP3001415-DNA_H04
D11718 83 female Not specified not recorded unknown unknown unknown primary NA NA Negative NA 73 Negative NA 0.7 NA NA European Dundee LP3001415-DNA_H05
D11719 49 female Not specified premenopausal unknown unknown unknown primary NA NA Negative Grade 3 14 Negative Alive 1.1 NA NA European Dundee LP3001415-DNA_D01
D11766 77 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 85 Negative Dead 0.3 NA NA European Dundee LP3001415-DNA_D02
D12258 46 female Not specified premenopausal unknown unknown unknown primary NA NA Negative Grade 3 15 Negative Alive 0.7 NA NA European Dundee LP3001415-DNA_D03
D12419 53 female Not specified perimenopausal unknown unknown unknown primary NA NA Negative Grade 2 25 Positive Alive 1.2 NA NA European Dundee LP3001415-DNA_D04
D12507 73 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 3 21 Negative Alive 0.7 NA NA European Dundee LP3001415-DNA_G05
D12646 36 female Not specified premenopausal unknown unknown unknown primary NA NA Negative Grade 3 22 Negative Alive 0.5 NA NA European Dundee LP3001415-DNA_D06
D12695 52 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 2 2 Negative Alive 2.1 NA NA European Dundee LP3001415-DNA_E01
D12775 53 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 29 Negative Alive 0.7 NA NA European Dundee LP3001415-DNA_E02
D12815 62 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 100 Positive Alive 0.7 NA NA European Dundee LP3001415-DNA_E04
D12883 46 female Not specified premenopausal unknown unknown unknown primary NA NA Negative Grade 1 11 NA Alive 0.8 NA NA European Dundee LP3001415-DNA_E05
D12903 64 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 3 45 Positive Alive 0.8 NA NA European Dundee LP3001415-DNA_E06
D13118 54 female Not specified perimenopausal unknown unknown unknown primary NA NA Negative Grade 3 39 Positive Alive 0.6 NA NA European Dundee LP3001415-DNA_F02
D13137 56 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 3 19 Negative Alive 0.4 NA NA European Dundee LP3001415-DNA_F03
D13337 66 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 33 Negative NA 0.2 NA NA European Dundee LP3001415-DNA_F04
D13350 68 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 2 8 Negative Alive 0.4 NA NA European Dundee LP3001415-DNA_B01
D13432 72 female Not specified not recorded unknown unknown unknown primary NA NA Negative Grade 3 0 Positive Alive 0.8 NA NA European Dundee LP3001415-DNA_F05
D13526 66 female Not specified postmenopausal unknown unknown unknown primary NA NA Negative Grade 3 20 Negative Alive 0.7 NA NA European Dundee LP3001415-DNA_F06
D9892 50 female Not specified premenopausal unknown unknown unknown primary NA NA Negative Grade 3 23 Positive Alive 3.7 NA NA European Dundee LP3001415-DNA_G06
LS12-098 45 female White - British premenopausal none recorded none recorded unknown primary Negative Negative Negative Grade 2 9 Negative Alive 5.6 NA NA European Leeds LP3001415-DNA_C02
LS12-122 78 female White - British postmenopausal none recorded none recorded unknown primary Negative Negative Negative Grade 3 17 Negative Alive 5.5 NA NA European Leeds LP3001415-DNA_G07
LS12-128 41 female White - British premenopausal none recorded none recorded unknown primary Negative Negative Negative Grade 3 16 Negative Alive 5.3 NA NA European Leeds LP3001415-DNA_F01
LS12-297 78 female White - British postmenopausal yes yes unknown primary Negative Negative Negative Grade 3 45 Negative Dead 3.5 yes yes European Leeds LP3001415-DNA_H01
LS12-379 68 female White - British postmenopausal none recorded none recorded unknown primary Negative Negative Negative Grade 3 40 Negative Alive 5.3 yes yes European Leeds LP3001415-DNA_A02
LS12-417 64 female White - British postmenopausal none recorded none recorded unknown primary Negative Negative Negative Grade 2 1.5 NA Alive 4.4 NA NA European Leeds LP3001415-DNA_B11
LS13-03209 54 female White - British premenopausal none recorded none recorded unknown primary Negative Negative Negative Grade 3 60 Positive Dead 1.3 yes yes European Leeds LP3001415-DNA_A04
LS13-03399 61 female White - British postmenopausal none recorded none recorded unknown primary Negative Negative Negative Grade 3 19 Negative Alive 4.1 NA NA European Leeds LP3001415-DNA_B02
LS13-03477 69 female White - Any other background not recorded none recorded none recorded unknown primary NA NA NA Grade 3 NS Negative Alive NA NA NA European Leeds LP3001415-DNA_A05
LS14-02842 69 female White - British not recorded yes yes unknown primary Negative Negative Negative Grade 3 130 Positive Dead 0.25 NA yes European Leeds LP3001415-DNA_B06
LS15-02515 48 female White - British perimenopausal unknown unknown unknown primary Negative Negative Negative Grade 3 19 Negative Alive 2.33 NA NA European Leeds LP3001415-DNA_A03
LS15-02568 62 female White - British postmenopausal yes no unknown recurrence Negative Negative Negative Grade 3 9 Negative Alive 3.0 NA NA European Leeds LP3001415-DNA_G01
LS16-4577 51 female White - British perimenopausal none recorded none recorded unknown primary Negative Negative Negative Grade 3 27 Positive Alive 1.08 NA NA European Leeds LP3001415-DNA_B03
LS16-4682 60 female White - British postmenopausal yes yes unknown primary Negative Negative Negative Grade 3 24 Positive Alive 0.75 NA NA European Leeds LP3001415-DNA_B04
LS17-4826 42 female White - British not recorded yes no unknown primary Negative Negative Negative Grade 3 42 Negative Alive 0.67 NA NA European Leeds LP3001415-DNA_B05
N12/001605 59 female White - British unknown unknown unknown NA primary Negative Negative Negative Grade 3 13 Negative Alive 6.42 NA NA European Nottingham LP3001415-DNA_G09
N12/001734 37 female White - British unknown not recorded not recorded unknown primary Positive Negative Negative Grade 3 20 Negative Alive 5.0 NA NA European Nottingham LP3001415-DNA_D10
N12/003761 50 female White - British postmenopausal not recorded not recorded unknown primary Negative Negative Negative Grade 3 25 Negative Alive 5.67 NA NA European Nottingham LP3001415-DNA_H06
N13/000457 61 female White - British unknown no no unknown primary Positive Negative Negative Grade 2 13 Negative Alive 6.33 NA CL European Nottingham LP3001381-DNA_D01
N13/000560 49 female White - British postmenopausal yes yes negative contralateral Negative Negative Negative Grade 3 16 Positive Alive 6.0 NA yes European Nottingham LP3001415-DNA_E09
N13/005968 45 female White - British premenopausal yes yes BRCA1 primary Negative Negative Negative Grade 3 26 Negative Alive 5.58 NA NA European Nottingham LP3001415-DNA_A06
N14/001416 49 female White - British postmenopausal unknown unknown unknown contralateral Negative Negative Negative Grade 3 24 Negative Dead 4.0 NA CL European Nottingham LP3001415-DNA_E10
N14/001950 71 female White - British unknown unknown unknown unknown primary Negative Negative Negative Grade 3 31 Negative Alive 3.25 NA NA European Nottingham LP3001415-DNA_E08
N14/002100 54 female White - British unknown unknown unknown unknown primary Negative Negative Negative Grade 3 50 Negative Dead 4.08 NA NA European Nottingham LP3001415-DNA_D09
N16/000331 50 female White - British postmenopausal no no unknown primary Negative Negative Negative Grade 3 18 Negative Dead 3.58 yes yes European Nottingham LP3001415-DNA_H10
N17/008421 51 female White - British unknown yes yes negative primary Negative Negative Negative Grade 3 27 Positive Alive 2.17 NA NA European Nottingham LP3001415-DNA_C07

There are patients available from the BCN Tissue Bank that match the selected/a subset of the criteria. Explore the data available for these patients using our Sample Finder

Overview
Help
Patient Statistics
Age at Diagnosis
Ethnicity
Survival Status
Menopausal Status
Tumour Statistics
Grade
ER Status
PR Status
HER2 Status
Cohort Summary
Variant Identification
Oncoplot help
LolliPlot help
Loading...
Somatic Interactions help
TCGA Compare help
Drug Prediction
Cancer Genome Interpreter (CGI) help
CGI Biomarker CGI Bioactivity
Gene Protein Alteration Alteration Match Drug Effect Tumour Evidence
TMPRSS2 K379R Different Alteration DNA-PKc inhibitor Responsive PRAD Pre-clinical
TMPRSS2 K379R Different Alteration PARP inhibitor Responsive PRAD Pre-clinical
FGFR2 intron_variant Different Alteration FGFR inhibitor Responsive COREAD Early trials
FGFR2 intron_variant Different Alteration FGFR inhibitor Responsive BT Early trials
NTRK3 intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
ERBB4 intron_variant), ERBB4 MUT* (intron_variant Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
RET intron_variant), RET MUT* (intron_variant Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET intron_variant), RET MUT* (intron_variant Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET intron_variant), RET MUT* (intron_variant Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET intron_variant), RET MUT* (intron_variant Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET intron_variant), RET MUT* (intron_variant Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET intron_variant), RET MUT* (intron_variant Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET intron_variant), RET MUT* (intron_variant Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET intron_variant), RET MUT* (intron_variant Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET intron_variant), RET MUT* (intron_variant Different Alteration RET inhibitor Responsive TH Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK intron_variant), ALK MUT* (intron_variant Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor Responsive COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
AKT3 intron_variant Different Alteration ATP competitive AKT inhibitor Responsive BRCA Pre-clinical
PDGFB intron_variant Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive DFS FDA guidelines
TP53 R175H Complete Match HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R175H Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R175H Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R175H Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R175H Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R175H Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R175H Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R175H Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R175H Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R175H Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R175H Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R175H Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R175H Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R175H Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R175H Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NTRK3 intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_varian Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_varian Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_varian Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
ERBB4 intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
PDGFRA intron_variant Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive MDPS, MDS, ECL, HES FDA guidelines
JAK2 intron_variant Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor Responsive COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
AKT3 intron_variant), AKT3 MUT* (intron_variant Different Alteration ATP competitive AKT inhibitor Responsive BRCA Pre-clinical
ESR1 intron_variant Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
MET intron_variant), MET MUT* (intron_variant), MET MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
BCR intron_variant Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
BCR intron_variant Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
BCR intron_variant Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR intron_variant Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR intron_variant Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
BCR intron_variant Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ESR1 3-UTRSNV Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
EGFR intron_variant Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR intron_variant Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
MET intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
NRG1 intron_variant Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 intron_variant Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
TMPRSS2 intron_variant Different Alteration DNA-PKc inhibitor Responsive PRAD Pre-clinical
TMPRSS2 intron_variant Different Alteration PARP inhibitor Responsive PRAD Pre-clinical
ERBB4 intron_variant Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
RET intron_variant Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET intron_variant Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET intron_variant Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET intron_variant Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET intron_variant Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET intron_variant Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET intron_variant Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET intron_variant Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET intron_variant Different Alteration RET inhibitor Responsive TH Pre-clinical
AKT3 intron_variant), AKT3 MUT* (intron_variant), AKT3 MUT* (intron_variant Different Alteration ATP competitive AKT inhibitor Responsive BRCA Pre-clinical
NTRK1 intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 intron_variant Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 intron_variant Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 intron_variant Different Alteration Pan-TK inhibitor Responsive COREAD Case report
JAK2 intron_variant), JAK2 MUT* (intron_variant Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
NRG1 intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 intron_variant), NRG1 MUT* (intron_variant), NRG1 MUT* (intron_variant Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
JAK2 L712V), JAK2 MUT* (intron_variant Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
PML intron_variant), PML MUT* (intron_variant Different Alteration Volasertib (PLK1 inhibitor) Responsive AML Early trials
PML intron_variant), PML MUT* (intron_variant Different Alteration Tretinoin (Retinoid) Responsive APML FDA guidelines
PML intron_variant), PML MUT* (intron_variant Different Alteration Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) Responsive AML FDA guidelines
ERBB4 intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (intron_varian Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration ALK inhibitor Responsive COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
STAG2 E756* Complete Match PARP inhibitor Responsive G Pre-clinical
BCR 3-UTRSNV Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
BCR 3-UTRSNV Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
BCR 3-UTRSNV Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR 3-UTRSNV Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR 3-UTRSNV Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
BCR 3-UTRSNV Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
TP53 Y327* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y327* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y327* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y327* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y327* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y327* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y327* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y327* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y327* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y327* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y327* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y327* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y327* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y327* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y327* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NTRK3 intron_variant), NTRK3 MUT* (D193V), NTRK3 MUT* (intron_variant), NTRK3 MUT* (IntronicBlockSubstitut Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant), NTRK3 MUT* (D193V), NTRK3 MUT* (intron_variant), NTRK3 MUT* (IntronicBlockSubstitut Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant), NTRK3 MUT* (D193V), NTRK3 MUT* (intron_variant), NTRK3 MUT* (IntronicBlockSubstitut Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
RAF1 intron_variant Different Alteration Sorafenib (Pan-TK inhibitor) Responsive PRAD Pre-clinical
RAF1 intron_variant Different Alteration Pan-RAF inhibitor Responsive PRAD Pre-clinical
RAF1 intron_variant Different Alteration U0126 (MEK inhibitor) Responsive PRAD Pre-clinical
ESR1 intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant), Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
EGFR intron_variant), EGFR MUT* (intron_variant Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR intron_variant), EGFR MUT* (intron_variant Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
ROS1 intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 intron_variant Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 intron_variant Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
BRAF E275Q Different Alteration Sorafenib (Pan-TK inhibitor) Responsive CM, LUAD, PRAD Pre-clinical
BRAF E275Q Different Alteration MEK inhibitor Responsive LUAD, CM, PRAD Pre-clinical
BRAF E275Q Different Alteration Selumetinib (MEK inhibitor) Responsive OV Case report
BRAF E275Q Different Alteration BRAF inhibitor;MEK inhibitor Responsive LUAD Case report
PML intron_variant Different Alteration Volasertib (PLK1 inhibitor) Responsive AML Early trials
PML intron_variant Different Alteration Tretinoin (Retinoid) Responsive APML FDA guidelines
PML intron_variant Different Alteration Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) Responsive AML FDA guidelines
NTRK3 intron_variant), NTRK3 MUT* (intron_variant Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant), NTRK3 MUT* (intron_variant Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant), NTRK3 MUT* (intron_variant Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
TP53 R248W Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R248W Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R248W Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R248W Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R248W Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R248W Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248W Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248W Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248W Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R248W Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R248W Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R248W Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248W Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R248W Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248W Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
BRD4 intron_variant Different Alteration BET inhibitor Responsive NMC Case report
ALK intron_variant Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK intron_variant Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK intron_variant Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK intron_variant Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK intron_variant Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK intron_variant Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK intron_variant Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK intron_variant Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK intron_variant Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK intron_variant Different Alteration ALK inhibitor Responsive COREAD Case report
ALK intron_variant Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
NOTCH2 intron_variant Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ABL1 intron_variant Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
ABL1 intron_variant Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ABL1 intron_variant Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
ABL1 intron_variant Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
ABL1 intron_variant Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
ABL1 intron_variant Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
PDGFRA 3-UTRSNV Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive MDPS, MDS, ECL, HES FDA guidelines
TP53 E198* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 E198* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 E198* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 E198* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 E198* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 E198* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 E198* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E198* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E198* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 E198* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 E198* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 E198* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E198* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 E198* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E198* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KMT2A R160L Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A R160L Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A R160L Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A R160L Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A R160L Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A R160L Different Alteration DOT1L inhibitor Responsive AML Early trials
NOTCH1 intron_variant Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 intron_variant Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ESR1 intron_variant), ESR1 MUT* (intron_variant Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
BCR intron_variant), BCR MUT* (intron_variant Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
BCR intron_variant), BCR MUT* (intron_variant Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
BCR intron_variant), BCR MUT* (intron_variant Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR intron_variant), BCR MUT* (intron_variant Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR intron_variant), BCR MUT* (intron_variant Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
BCR intron_variant), BCR MUT* (intron_variant Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ESR1 intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
ROS1 intron_variant), ROS1 MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 intron_variant), ROS1 MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 intron_variant), ROS1 MUT* (intron_variant Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 intron_variant), ROS1 MUT* (intron_variant Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 intron_variant), ROS1 MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
RET 3-UTRSNV Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET 3-UTRSNV Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET 3-UTRSNV Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET 3-UTRSNV Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET 3-UTRSNV Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET 3-UTRSNV Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET 3-UTRSNV Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET 3-UTRSNV Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET 3-UTRSNV Different Alteration RET inhibitor Responsive TH Pre-clinical
MET intron_variant), MET MUT* (IntronicBlockSubstitution Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
NRG1 intron_variant), NRG1 MUT* (intron_variant Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 intron_variant), NRG1 MUT* (intron_variant Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
NOTCH2 intron_variant), NOTCH2 MUT* (Q1136E), NOTCH2 MUT* (intron_variant), NOTCH2 MUT* (intron_variant), N Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
TP53 P278L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P278L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P278L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P278L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P278L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P278L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P278L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P278L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P278L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P278L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P278L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P278L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P278L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P278L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P278L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PTEN R130P Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD Case report
PTEN R130P Different Mutation Panitumumab (EGFR mAb inhibitor) Resistant COREAD Case report
PTEN R130P Different Mutation BYL719 (PIK3CA inhibitor) Resistant BRCA Case report
PTEN R130P Complete Match ATM inhibitor Responsive BRCA Pre-clinical
PTEN R130P Complete Match PI3K pathway inhibitor Responsive BRCA, ED, TH, CANCER, L, G, OV Pre-clinical
PTEN R130P Complete Match EGFR mAb inhibitor Resistant COREAD Late trials
PTEN R130P Complete Match Sirolimus (MTOR inhibitor) Responsive CANCER Early trials
PTEN R130P Complete Match PARP inhibitor Responsive ED Case report
PTEN R130P Complete Match PD1 Ab inhibitor Resistant CM Early trials
PTEN R130P Complete Match PI3K pathway inhibitor;AR antagonist Responsive PRAD Pre-clinical
PTEN R130P Complete Match Everolimus (MTOR inhibitor) Responsive PRAD Early trials
PTEN R130P Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive OV Pre-clinical
PTEN R130P Complete Match PIK3CB inhibitor Responsive PRAD Case report
PTEN R130P Complete Match AKT inhibitor Responsive PA Case report
PTEN R130P Complete Match MTOR inhibitor No Responsive ED Early trials
PTEN R130P Different Alteration PI3K pathway inhibitor Responsive L, BRCA, CANCER, G, ED, TH, OV Pre-clinical
PTEN R130P Different Alteration Everolimus (MTOR inhibitor) Responsive PRAD Early trials
PTEN R130P Different Alteration Sirolimus (MTOR inhibitor) Responsive CANCER Early trials
PTEN R130P Different Alteration PARP inhibitor Responsive ED Case report
PTEN R130P Different Alteration PIK3CB inhibitor Responsive PRAD Case report
PTEN R130P Different Alteration EGFR mAb inhibitor Resistant COREAD Late trials
PTEN R130P Different Alteration MTOR inhibitor No Responsive ED Early trials
PTEN R130P Different Alteration AKT inhibitor Responsive PA Case report
PTEN R130P Different Alteration PI3K pathway inhibitor;AR antagonist Responsive PRAD Pre-clinical
PTEN R130P Different Alteration PI3K pathway inhibitor;MEK inhibitor Responsive OV Pre-clinical
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration ALK inhibitor Responsive COREAD Case report
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK IntronicBlockSubstitution), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_v Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
AKT3 intron_variant), AKT3 MUT* (intron_variant), AKT3 MUT* (intron_variant), AKT3 MUT* (intron_variant Different Alteration ATP competitive AKT inhibitor Responsive BRCA Pre-clinical
TP53 D281N Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 D281N Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 D281N Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 D281N Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 D281N Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 D281N Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 D281N Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 D281N Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 D281N Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 D281N Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 D281N Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 D281N Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 D281N Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 D281N Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 D281N Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration ALK inhibitor Responsive COREAD Case report
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), ALK MUT* (intron_variant), AL Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
MET IntronicBlockSubstitution), MET MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
KMT2A intron_variant Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A intron_variant Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A intron_variant Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A intron_variant Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A intron_variant Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A intron_variant Different Alteration DOT1L inhibitor Responsive AML Early trials
FGFR3 S344F Different Alteration FGFR inhibitor Responsive BLCA Case report
FGFR3 S344F Different Alteration FGFR inhibitor Responsive G Early trials
FGFR3 S344F Different Alteration FGFR inhibitor Responsive NSCLC Pre-clinical
TP53 R273H Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R273H Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R273H Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R273H Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R273H Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R273H Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R273H Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273H Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273H Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R273H Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R273H Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R273H Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273H Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R273H Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273H Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
JAK2 intron_variant), JAK2 MUT* (5-UTRSNV Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
EGFR M1007I Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR M1007I Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
NTRK3 intron_variant Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
BRCA2 L2480* Complete Match PD1 Ab inhibitor Responsive CM Case report
BRCA2 L2480* Complete Match Olaparib (PARP inhibitor) Responsive OV FDA guidelines
BRCA2 L2480* Complete Match Platinum Agent (Chemotherapy) Responsive OV Late trials
BRCA2 L2480* Complete Match Chemotherapy (PARP inhibitor;Chemotherapy) Responsive OV Early trials
BRCA2 L2480* Complete Match PARP inhibitor;Chemotherapy Responsive OV Early trials
BRCA2 L2480* Complete Match Platinum Agent (Chemotherapy) Responsive PA Case report
BRCA2 L2480* Complete Match Olaparib (PARP inhibitor) Responsive PRAD Early trials
BRCA2 L2480* Complete Match Rucaparib (PARP inhibitor) Responsive OV FDA guidelines
BRCA2 L2480* Complete Match PD1/PDL1 inhibitor Responsive UTH Early trials
BRCA2 L2480* Complete Match Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) Responsive BRCA Early trials
BRCA2 L2480* Complete Match Platinum Agent (Chemotherapy) Responsive BRCA Early trials
BRCA2 L2480* Complete Match PARP inhibitor Responsive BRCA Early trials
BRCA2 L2480* Different Alteration PD1/PDL1 inhibitor Responsive UTH Early trials
BRCA2 L2480* Different Alteration PARP inhibitor Responsive OV Pre-clinical
ERBB4 intron_variant), ERBB4 MUT* (intron_variant), ERBB4 MUT* (3-UTRSNV Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
CRLF2 intron_variant Different Alteration MTOR inhibitor Responsive ALL Pre-clinical
CRLF2 intron_variant Different Alteration BET inhibitor Responsive ALL Pre-clinical
NOTCH2 R2298R Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
TP53 L257P Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 L257P Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 L257P Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 L257P Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 L257P Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 L257P Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 L257P Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 L257P Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 L257P Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 L257P Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 L257P Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 L257P Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 L257P Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 L257P Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 L257P Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NOTCH2 intron_variant), NOTCH2 MUT* (intron_variant Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ESR1 intron_variant), ESR1 MUT* (IntronicBlockSubstitution Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
TP53 splice_donor_variant Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 splice_donor_variant Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 splice_donor_variant Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 splice_donor_variant Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 splice_donor_variant Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 splice_donor_variant Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 splice_donor_variant Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 splice_donor_variant Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 splice_donor_variant Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_donor_variant Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 splice_donor_variant Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_donor_variant Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PTEN splice_acceptor_variant Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD Case report
PTEN splice_acceptor_variant Different Mutation Panitumumab (EGFR mAb inhibitor) Resistant COREAD Case report
PTEN splice_acceptor_variant Different Mutation BYL719 (PIK3CA inhibitor) Resistant BRCA Case report
PTEN splice_acceptor_variant Complete Match ATM inhibitor Responsive BRCA Pre-clinical
PTEN splice_acceptor_variant Complete Match PI3K pathway inhibitor Responsive BRCA, ED, TH, CANCER, L, G, OV Pre-clinical
PTEN splice_acceptor_variant Complete Match EGFR mAb inhibitor Resistant COREAD Late trials
PTEN splice_acceptor_variant Complete Match Sirolimus (MTOR inhibitor) Responsive CANCER Early trials
PTEN splice_acceptor_variant Complete Match PARP inhibitor Responsive ED Case report
PTEN splice_acceptor_variant Complete Match PD1 Ab inhibitor Resistant CM Early trials
PTEN splice_acceptor_variant Complete Match PI3K pathway inhibitor;AR antagonist Responsive PRAD Pre-clinical
PTEN splice_acceptor_variant Complete Match Everolimus (MTOR inhibitor) Responsive PRAD Early trials
PTEN splice_acceptor_variant Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive OV Pre-clinical
PTEN splice_acceptor_variant Complete Match PIK3CB inhibitor Responsive PRAD Case report
PTEN splice_acceptor_variant Complete Match AKT inhibitor Responsive PA Case report
PTEN splice_acceptor_variant Complete Match MTOR inhibitor No Responsive ED Early trials
PTEN splice_acceptor_variant Different Alteration PI3K pathway inhibitor Responsive L, BRCA, CANCER, G, ED, TH, OV Pre-clinical
PTEN splice_acceptor_variant Different Alteration Everolimus (MTOR inhibitor) Responsive PRAD Early trials
PTEN splice_acceptor_variant Different Alteration Sirolimus (MTOR inhibitor) Responsive CANCER Early trials
PTEN splice_acceptor_variant Different Alteration PARP inhibitor Responsive ED Case report
PTEN splice_acceptor_variant Different Alteration PIK3CB inhibitor Responsive PRAD Case report
PTEN splice_acceptor_variant Different Alteration EGFR mAb inhibitor Resistant COREAD Late trials
PTEN splice_acceptor_variant Different Alteration MTOR inhibitor No Responsive ED Early trials
PTEN splice_acceptor_variant Different Alteration AKT inhibitor Responsive PA Case report
PTEN splice_acceptor_variant Different Alteration PI3K pathway inhibitor;AR antagonist Responsive PRAD Pre-clinical
PTEN splice_acceptor_variant Different Alteration PI3K pathway inhibitor;MEK inhibitor Responsive OV Pre-clinical
NOTCH1 H2428Pfs*5 Complete Match Gamma secretase inhibitor Responsive CANCER Early trials
NOTCH1 H2428Pfs*5 Complete Match Gamma secretase inhibitor;CDK4 inhibitor Responsive ALL Pre-clinical
NOTCH1 H2428Pfs*5 Complete Match Gamma secretase inhibitor;MTOR inhibitor Responsive ALL Pre-clinical
NOTCH1 H2428Pfs*5 Complete Match Gamma secretase inhibitor Responsive;Responsive ALL Early trials;Pre-clinical
NOTCH1 H2428Pfs*5 Complete Match NOTCH1 inhibitor Responsive ADCC Case report
NOTCH1 H2428Pfs*5 Complete Match OMP-52M51 (NOTCH1 inhibitor) Responsive CANCER Early trials
NOTCH1 H2428Pfs*5 Complete Match Gamma secretase inhibitor Responsive BRCA Pre-clinical
NOTCH1 H2428Pfs*5 Complete Match Gamma secretase inhibitor Responsive MCL Pre-clinical
NOTCH1 H2428Pfs*5 Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 H2428Pfs*5 Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
FGFR2 intron_variant), FGFR2 MUT* (intron_variant Different Alteration FGFR inhibitor Responsive COREAD Early trials
FGFR2 intron_variant), FGFR2 MUT* (intron_variant Different Alteration FGFR inhibitor Responsive BT Early trials
TP53 I255T Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 I255T Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 I255T Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 I255T Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 I255T Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 I255T Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 I255T Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I255T Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I255T Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 I255T Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 I255T Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 I255T Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I255T Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 I255T Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I255T Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
FGFR3 3-UTRSNV Different Alteration FGFR inhibitor Responsive BLCA Case report
FGFR3 3-UTRSNV Different Alteration FGFR inhibitor Responsive G Early trials
FGFR3 3-UTRSNV Different Alteration FGFR inhibitor Responsive NSCLC Pre-clinical
PTEN R130Q Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD Case report
PTEN R130Q Different Mutation Panitumumab (EGFR mAb inhibitor) Resistant COREAD Case report
PTEN R130Q Different Mutation BYL719 (PIK3CA inhibitor) Resistant BRCA Case report
PTEN R130Q Complete Match ATM inhibitor Responsive BRCA Pre-clinical
PTEN R130Q Complete Match PI3K pathway inhibitor Responsive BRCA, ED, TH, CANCER, L, G, OV Pre-clinical
PTEN R130Q Complete Match EGFR mAb inhibitor Resistant COREAD Late trials
PTEN R130Q Complete Match Sirolimus (MTOR inhibitor) Responsive CANCER Early trials
PTEN R130Q Complete Match PARP inhibitor Responsive ED Case report
PTEN R130Q Complete Match PD1 Ab inhibitor Resistant CM Early trials
PTEN R130Q Complete Match PI3K pathway inhibitor;AR antagonist Responsive PRAD Pre-clinical
PTEN R130Q Complete Match Everolimus (MTOR inhibitor) Responsive PRAD Early trials
PTEN R130Q Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive OV Pre-clinical
PTEN R130Q Complete Match PIK3CB inhibitor Responsive PRAD Case report
PTEN R130Q Complete Match AKT inhibitor Responsive PA Case report
PTEN R130Q Complete Match MTOR inhibitor No Responsive ED Early trials
PTEN R130Q Different Alteration PI3K pathway inhibitor Responsive L, BRCA, CANCER, G, ED, TH, OV Pre-clinical
PTEN R130Q Different Alteration Everolimus (MTOR inhibitor) Responsive PRAD Early trials
PTEN R130Q Different Alteration Sirolimus (MTOR inhibitor) Responsive CANCER Early trials
PTEN R130Q Different Alteration PARP inhibitor Responsive ED Case report
PTEN R130Q Different Alteration PIK3CB inhibitor Responsive PRAD Case report
PTEN R130Q Different Alteration EGFR mAb inhibitor Resistant COREAD Late trials
PTEN R130Q Different Alteration MTOR inhibitor No Responsive ED Early trials
PTEN R130Q Different Alteration AKT inhibitor Responsive PA Case report
PTEN R130Q Different Alteration PI3K pathway inhibitor;AR antagonist Responsive PRAD Pre-clinical
PTEN R130Q Different Alteration PI3K pathway inhibitor;MEK inhibitor Responsive OV Pre-clinical
ROS1 intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant), ROS1 MUT* (intron_variant Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
MET IntronicBlockSubstitution Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
JAK2 IntronicBlockSubstitution Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
NOTCH1 Q1766H Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 Q1766H Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
FGFR2 5-UTRSNV Different Alteration FGFR inhibitor Responsive COREAD Early trials
FGFR2 5-UTRSNV Different Alteration FGFR inhibitor Responsive BT Early trials
KMT2D R1252* Complete Match Bicalutamide (AR inhibitor) Responsive LUSC Pre-clinical
EGFR 3-UTRSNV Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR 3-UTRSNV Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
TP53 P278S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P278S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P278S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P278S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P278S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P278S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P278S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P278S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P278S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P278S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P278S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P278S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P278S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P278S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P278S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ESR1 3-UTRSNV), ESR1 MUT* (intron_variant Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
TP53 V216M Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V216M Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V216M Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V216M Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V216M Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V216M Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V216M Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V216M Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V216M Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V216M Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V216M Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V216M Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V216M Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V216M Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V216M Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
BRAF intron_variant Different Alteration Sorafenib (Pan-TK inhibitor) Responsive CM, LUAD, PRAD Pre-clinical
BRAF intron_variant Different Alteration MEK inhibitor Responsive LUAD, CM, PRAD Pre-clinical
BRAF intron_variant Different Alteration Selumetinib (MEK inhibitor) Responsive OV Case report
BRAF intron_variant Different Alteration BRAF inhibitor;MEK inhibitor Responsive LUAD Case report
PIK3CA H1047R Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA H1047R Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA H1047R Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA H1047R Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA H1047R Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA H1047R Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA H1047R Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA H1047R Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA H1047R Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA H1047R Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA H1047R Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA H1047R Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA H1047R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA H1047R Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
EGFR S229C Different Alteration Cetuximab (EGFR mAb inhibitor) Responsive COREAD FDA guidelines
EGFR S229C Different Alteration Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
EGFR S229C Different Mutation Rindopepimut (Vaccine) Responsive GB Late trials
EGFR S229C Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Responsive NSCLC FDA guidelines
EGFR S229C Different Mutation Gefitinib (EGFR inhibitor) Responsive NSCLC FDA guidelines
EGFR S229C Different Mutation HSP90 inhibitor Responsive L Early trials
EGFR S229C Different Mutation Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) Responsive L Early trials
EGFR S229C Different Mutation MEK inhibitor Responsive L Pre-clinical
EGFR S229C Different Mutation EGFR TK inhibitor Responsive L Late trials
EGFR S229C Different Mutation Erlotinib (EGFR inhibitor) Responsive NSCLC NCCN guidelines
EGFR S229C Different Mutation Osimertinib (EGFR inhibitor) Resistant L Early trials
EGFR S229C Different Mutation EGFR-TKI's (EGFR inhibitor) Resistant L Late trials
EGFR S229C Different Mutation HSP90 inhibitor Responsive L Case report
EGFR S229C Different Mutation EGFR inhibitor Resistant L Late trials
EGFR S229C Different Mutation Poziotinib (EGFR inhibitor) Responsive L Early trials
EGFR S229C Different Mutation Osimertinib (EGFR inhibitor) Responsive L Pre-clinical
EGFR S229C Different Mutation HSP90 inhibitor (HSP90 inhibitor) Responsive L Early trials
EGFR S229C Different Mutation Erlotinib (EGFR inhibitor) Responsive G Pre-clinical
EGFR S229C Different Mutation Erlotinib (EGFR inhibitor) Responsive NSCLC FDA guidelines
EGFR S229C Different Mutation Osimertinib (EGFR inhibitor) Responsive L Early trials
EGFR S229C Different Mutation Rociletinib (EGFR inhibitor) Resistant LUAD Case report
EGFR S229C Different Mutation Panitumumab (EGFR mAb inhibitor) Responsive COREAD Case report
EGFR S229C Different Mutation novel EGFR mAb inhibitor Responsive COREAD Early trials
EGFR S229C Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD Case report
EGFR S229C Different Mutation Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) Responsive HNC Case report
EGFR S229C Different Mutation Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR S229C Different Mutation Gefitinib (EGFR inhibitor) No Responsive HNC Case report
EGFR S229C Different Mutation EGFR inhibitor Responsive L Early trials
EGFR S229C Different Mutation Erlotinib (EGFR inhibitor) Resistant L NCCN/CAP guidelines
EGFR S229C Different Mutation Osimertinib (EGFR inhibitor) Responsive NSCLC FDA guidelines
EGFR S229C Different Mutation EGFR inhibitor Responsive NSCLC Late trials
EGFR S229C Different Mutation Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) Responsive L Early trials
EGFR S229C Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Resistant L NCCN/CAP guidelines
EGFR S229C Different Mutation Erlotinib (EGFR inhibitor) Responsive L Early trials
EGFR S229C Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Responsive L Late trials
EGFR S229C Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD Pre-clinical
EGFR S229C Different Mutation Erlotinib (EGFR inhibitor) No Responsive L Case report
EGFR S229C Different Mutation Lapatinib (ERBB2 inhibitor) Responsive ED Case report
EGFR S229C Different Mutation EGFR inhibitor No Responsive G Early trials
EGFR S229C Different Mutation EGFR inhibitor Resistant NSCLC Case report
EGFR S229C Different Mutation Panitumumab (EGFR mAb inhibitor) Resistant COREAD Case report
EGFR S229C Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant;Resistant COREAD Pre-clinical;Case report
EGFR S229C Different Mutation Cetuximab (EGFR mAb inhibitor) Responsive HNC Case report
EGFR S229C Different Alteration Gefitinib (EGFR inhibitor) Responsive ED Late trials
EGFR S229C Different Alteration Gefitinib (EGFR inhibitor) No Responsive HNC Early trials
EGFR S229C Different Alteration EGFR inhibitor Responsive HNSC Case report
EGFR S229C Different Alteration EGFR inhibitor No Responsive G Early trials
EGFR S229C Different Alteration Erlotinib (EGFR inhibitor) No Responsive L Early trials
EGFR S229C Different Alteration EGFR mAb inhibitor Responsive COREAD Late trials
EGFR S229C Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR S229C Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
ESR1 intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant), ESR1 MUT* (intron_variant Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
ERBB2 V777L Different Alteration Pertuzumab (ERBB2 mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V777L Different Alteration Lapatinib (ERBB2 inhibitor) Responsive BRCA FDA guidelines
ERBB2 V777L Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive ST, BRCA, GEJA FDA guidelines
ERBB2 V777L Different Alteration Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V777L Different Alteration MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) Responsive SOLID Early trials
ERBB2 V777L Complete Match Lapatinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V777L Complete Match Neratinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V777L Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive CANCER, BRCA Pre-clinical
ERBB2 V777L Different Mutation Neratinib (ERBB2 inhibitor) Responsive CANCER Early trials
ERBB2 V777L Complete Match Neratinib (ERBB2 inhibitor) Responsive CANCER Early trials
ERBB2 V777L Different Mutation Neratinib (ERBB2 inhibitor) Responsive BRCA Case report
ERBB2 V777L Different Mutation Lapatinib (ERBB2 inhibitor) Responsive BRCA, LUAD Case report
ERBB2 V777L Different Mutation Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive L Early trials
ERBB2 V777L Different Mutation Neratinib (ERBB2 inhibitor) Resistant BRCA Case report
ERBB2 V777L Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Responsive BRCA Pre-clinical
ERBB2 V777L Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive LUAD Case report
ERBB2 V777L Different Mutation Neratinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V777L Different Mutation Lapatinib (ERBB2 inhibitor) Resistant BRCA Pre-clinical
ERBB2 V777L Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive CANCER Pre-clinical
ERBB2 V777L Complete Match Temsirolimus (MTOR inhibitor) Responsive LUAD Early trials
ERBB2 V777L Complete Match Dacomitinib (Pan ERBB inhibitor) Responsive NSCLC Early trials
ERBB2 V777L Complete Match Neratinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V777L Different Mutation ERBB2 inhibitor Responsive LUAD Early trials
ERBB2 V777L Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Early trials
ERBB2 V777L Different Mutation ERBB2 mAb inhibitor Responsive LUAD Early trials
ERBB2 V777L Different Mutation Neratinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V777L Different Mutation Lapatinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V777L Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive LUAD Early trials
ERBB2 V777L Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive BRCA Late trials
ERBB2 V777L Different Alteration Pertuzumab (ERBB2 mAb inhibitor) Responsive BT Early trials
ERBB2 V777L Different Alteration Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Responsive COREAD Late trials
ERBB2 V777L Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive OV Early trials
ERBB2 V777L Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive BLCA Case report
ERBB2 V777L Different Alteration Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive COREAD Case report
ERBB2 V777L Different Alteration Rociletinib (EGFR inhibitor) Resistant LUAD Case report
ERBB2 V777L Different Alteration Osimertinib (EGFR inhibitor) Resistant LUAD Case report
ERBB2 V777L Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive BT Early trials
ERBB2 V777L Different Alteration EGFR mAb inhibitor Resistant COREAD Early trials
ERBB2 V777L Different Alteration Lapatinib (ERBB2 inhibitor) Responsive BT Early trials
ERBB2 V777L Different Alteration Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) Responsive BRCA